Annals of Internal Medicine · 1971 · 181 citations · 33 references
MedicinePharmacologyPharmacotherapyChemotherapyHypersensitivityOncology PharmacotherapyAnaphylaxisChemotherapy In Hematologic MalignanciesOncology PharmacologyAcute Leukemia ChemotherapyAcute LeukemiasAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentAsparaginase PharmacokineticsAsparaginase TherapyClinical RemissionPlasma Protein Synthesis
Forty patients with acute leukemia were treated with Intravenous L-asparaginase in doses ranging from 10 to 1,000 international units/kg body weight per day for 2 to 20 days. Most had long-standing disease and had exhausted conventional therapy. The remission rate appeared to be unaffected by dose, schedule, or previous chemotherapy. There was a 66% response rate for acute lymphoblastic leukemia and an approximately 12% response rate for nonlymphocytic leukemia. Second and third remissions were obtained. Toxicity was not strictly dose related and consisted of fever, anorexia, nausea, vomiting, decreased protein synthesis, biochemical hepatic dysfunction, elevated blood ammonia, nonketotic hyperglycemia, and anaphylaxis. Although there were two deaths directly attributed to L-asparaginase, most patients tolerated the enzyme well with very little impairment of performance status. The rapid clearance of plasma enzyme and the development of passive hemagglutinating and reagin types of antibodies are correlated with the development of anaphylaxis. The relationship of plasma L-asparagine to disease status is discussed.
33
L-Asparaginase Therapy for Leukemia and Other Malignant Neoplasms
Joseph M. Hill · JAMA · 1967 · 302 citations
Toxicity of E. coli L-asparaginase in man
Herbert F. Oettgen, Phyllis A. Stephenson, Morton K. Schwartz et al. · Cancer · 1970 · 287 citations · Full text